

**HD** Press Release: Avita Medical Announces Receipt of \$1.4 **Million** R&D Tax Incentive

**WC** 310 words

**PD** 11 November 2014

**ET** 21:30

**SN** Dow Jones Institutional News

**SC** DJDN

**LA** English

**CY** Copyright © 2014, Dow Jones & Company, Inc.

**LP**

Avita Medical Announces Receipt of \$1.4 **Million** R&D Tax Incentive

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - Nov 11, 2014) - Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMX) a regenerative medicine **company** specializing in the treatment of wounds and skin defects, today announced that it has received an Australian R&D Tax Incentive payment of \$1.4M for the financial year ending 30 June 2014.

**TD**

"The payment resulting from Australia's R&D Tax Incentive program provides an important additional resource to innovate new advancements and explore additional applications for our proprietary technology platform, ReCell(R) Spray-On Skin(R) ," commented Tim Rooney, Avita Medical's Interim Chief Executive Officer.

#### ABOUT AVITA MEDICAL LIMITED

Avita Medical (<http://www.avitamedical.com>) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue--culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The **Company's lead** product, ReCell(R) Spray--On Skin(R) , is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE--marked for Europe, TGA--registered in Australia, and SFDA--cleared in **China**. ReCell is not available for **sale** in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

#### FOR FURTHER INFORMATION:

Avita Medical Ltd.

Tim Rooney

Interim Chief Executive Officer/Chief Financial Officer

Phone: + 1 (818) 827-1695

Email: [trooney@avitamedical.com](mailto:trooney@avitamedical.com)

Avita Medical Ltd.

Lou Panaccio

Chairman

Phone: +61 (0) 8 9474 7738

Email: [lpnaccio@avitamedical.com](mailto:lpnaccio@avitamedical.com)

(END) Dow Jones Newswires

November 11, 2014 05:30 ET (10:30 GMT)

**CO** gchip : Avita Medical Limited

**IN** i257 : Pharmaceuticals | i951 : Health Care/Life Sciences

**NS** ccat : Corporate/Industrial News | neqac : Equities Asset Class News | npress : Press Releases | c23 : Research/Development | ncat : Content Types | nfact : Factiva Filters

**RE** austr : Australia | apacz : Asia Pacific | ausnz : Australia/Oceania

**PUB** Dow Jones & Company, Inc.

**AN** Document DJDN000020141111eabb001dv